Choroid melanoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:04:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Choroid melanoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Preventing Neovascular Glaucoma in Patients with Large Choroidal Melanoma Using Aflibercept During Proton Therapy https://clinicaltrials.eu/trial/preventing-neovascular-glaucoma-in-patients-with-large-choroidal-melanoma-using-aflibercept-during-proton-therapy/ Wed, 29 Apr 2026 14:58:47 +0000 https://clinicaltrials.eu/trial/preventing-neovascular-glaucoma-in-patients-with-large-choroidal-melanoma-using-aflibercept-during-proton-therapy/ This clinical trial is focused on studying a condition called neovascular glaucoma, which can occur in patients who have been treated for a type of eye cancer known as large choroid melanoma. This melanoma is a tumor located in the eye, and in this study, it is specifically those that are 7 mm thick or more, or have a basal diameter greater than 15 mm. The treatment for this melanoma involves a type of radiation therapy called proton therapy.

The study is investigating the use of a medication called aflibercept, which is also known by its brand name Eylea. Aflibercept is administered as an injection directly into the eye, known as an intravitreal injection. The purpose of the study is to see if aflibercept can help prevent neovascular glaucoma in patients who have undergone proton therapy for large choroid melanoma. Participants in the study will be divided into two groups: one group will receive the aflibercept injections, while the other group will receive a false injection, known as a placebo.

The study will follow participants for a period of five years after their proton therapy treatment to compare the rate of neovascular glaucoma between the two groups. This will help determine if the preventive use of aflibercept is effective in reducing the occurrence of this eye condition in patients with large choroid melanoma. The study aims to provide valuable insights into the potential benefits of using aflibercept as a preventive treatment in this context.

]]> Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-belzupacap-sarotalocan-for-patients-with-small-choroidal-melanoma-or-indeterminate-lesions/ Wed, 29 Apr 2026 14:29:17 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-belzupacap-sarotalocan-for-patients-with-small-choroidal-melanoma-or-indeterminate-lesions/ This clinical trial is focused on studying the treatment of Primary Indeterminate Lesions or Small Choroidal Melanoma, which are conditions affecting the eye. The treatment being tested is called Belzupacap Sarotalocan, also known by its code name AU-011. This medication is administered as a solution for injection using a special device called the Clearside SCS Microinjector, which delivers the medication into a specific part of the eye known as the suprachoroidal space.

The purpose of this study is to evaluate the effectiveness and safety of Belzupacap Sarotalocan compared to a placebo, which is a sham injection that does not contain the active medication. Participants in the study will receive either the active treatment or the placebo. The study will monitor the participants over a period to assess how the treatment affects the progression of the eye condition.

Throughout the study, participants will undergo regular check-ups to track the condition of their eye and overall health. The study aims to determine how well the treatment works in slowing down or stopping the growth of the lesions or melanoma, as well as ensuring that it is safe for use. The trial is expected to continue until 2027, with recruitment starting in 2024.

]]>